SEC Form 10-Q filed by AptarGroup Inc.

AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong third quarter results due to solid operational performance and margin improvement across the company. Results were driven by growth in proprietary drug delivery systems, as well as increased demand for closure technologies. Reported sales and core sales increased by 2%, as currency and acquisition effects did not impact the quarter. Aptar reported net income of $100 million for the quarter, a 19% increase from the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024363414/en/

AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, announced that it was awarded a contract from the U.S. Federal Government to advance development of its ActivShield™ technology. This innovative solution sterilizes medical devices and instruments without the need for a power source, making it a versatile solution for numerous environments, including rural areas, military settings and healthcare facilities with limited or no current sterilization capability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241022369874/en/Figure 1: ActivShield™ film ready to be

The Board of Directors of AptarGroup, Inc. (NYSE:ATR) authorized the repurchase of up to $500 million of the Company's common stock. This new authorization replaces all previous authorizations. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. The Board also declared a quarterly cash dividend of $0.45 per share. The payment date is November 14, 2024, to stockholders of record as of October 24, 2024. Stephan Tanda, President and CEO, commented, "Aptar maintains a balanced approach to capital allocation, focused on returning capital to shareholders, as well as reinvesting in the business through capacity ex

10-Q - APTARGROUP, INC. (0000896622) (Filer)

8-K - APTARGROUP, INC. (0000896622) (Filer)

10-Q - APTARGROUP, INC. (0000896622) (Filer)

AptarGroup's (NYSE:ATR) short percent of float has risen 20.34% since its last report. The company recently reported that it has 414 thousand shares sold short, which is 0.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.46 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is

Wells Fargo analyst Gabe Hajde maintains AptarGroup (NYSE:ATR) with a Overweight and raises the price target from $163 to $168.

The increase brings the new annualized dividend to $1.80 per share. The payment date is August 15, 2024, to stockholders of record as of July 25, 2024.

Jefferies upgraded AptarGroup from Hold to Buy and set a new price target of $215.00 from $155.00 previously

William Blair upgraded AptarGroup from Mkt Perform to Outperform

Robert W. Baird upgraded AptarGroup from Neutral to Outperform and set a new price target of $150.00 from $125.00 previously

SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)

SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)

SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)

4 - APTARGROUP, INC. (0000896622) (Issuer)

4 - APTARGROUP, INC. (0000896622) (Issuer)

4 - APTARGROUP, INC. (0000896622) (Issuer)

AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong third quarter results due to solid operational performance and margin improvement across the company. Results were driven by growth in proprietary drug delivery systems, as well as increased demand for closure technologies. Reported sales and core sales increased by 2%, as currency and acquisition effects did not impact the quarter. Aptar reported net income of $100 million for the quarter, a 19% increase from the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024363414/en/

The Board of Directors of AptarGroup, Inc. (NYSE:ATR) authorized the repurchase of up to $500 million of the Company's common stock. This new authorization replaces all previous authorizations. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. The Board also declared a quarterly cash dividend of $0.45 per share. The payment date is November 14, 2024, to stockholders of record as of October 24, 2024. Stephan Tanda, President and CEO, commented, "Aptar maintains a balanced approach to capital allocation, focused on returning capital to shareholders, as well as reinvesting in the business through capacity ex

AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported solid second quarter results driven by continued growth of the company's proprietary drug delivery systems and margin improvement. Reported sales increased by 2% and core sales, excluding currency and acquisition effects, increased by 3%. Aptar reported net income of $90 million for the quarter, a 9% increase from the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725389689/en/Photo: Aptar "Strong sales growth in our Pharma business and broad-based margin expansion helped us achi

Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,

AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905451175/en/Sarah Glickman Joins Aptar's Board of Directors (Photo: Aptar) "We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah's extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005172/en/Julie Xing Joins Aptar's Board of Directors (Photo: Aptar) With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie's leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple g